Corrections:

Suliman Boulos^1,*, Min Chul Park^2,*, Marian Zeibak³, Shen Yun Foo⁴, Yoon Kyung Jeon⁵, Young Tae Kim⁶, Alex Motzik³, Sagi Tshori⁷, Tamar Hamburger⁸, Sunghoon Kim², Hovav Nechushtan¹ and Ehud Razin^3,4

¹ Department of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel
² Medicinal Bioconvergence Research Center, Seoul National University, Seoul, Korea
³ Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, The Hebrew University of Jerusalem, Jerusalem, Israel
⁴ NUS-HUJ-CREATE Cellular & Molecular Mechanisms of Inflammation Program, Department of Microbiology and Immunology, National University of Singapore, Singapore
⁵ Department of Pathology, Seoul National University Hospital, Seoul, Korea
⁶ Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul, Korea
⁷ Kaplan Medical Center, Rehovot, Israel
⁸ Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel
^* These authors have contributed equally to this work

Published: November 16, 2018

This article has been corrected: The correct title for figure 5 is given below:

Figure 5: Subgroup analysis of nuclear P207 LysRS according to Lymph nodes positivity. Disease free survival of wild-type EGFR patients with (positive) or without (negative) cytosolic (A) and nuclear (B) LysRS. Disease free survival of mutated EGFR patients with (positive) or without (negative) cytosolic (C) and nuclear (D) LysRS.

Original article: Oncotarget. 2017; 8:65186-65198. DOI: https://doi.org/10.18632/oncotarget.18053.